Russell Greig becomes Syntaxin chairman


Has spent most of his career at GlaxoSmithKline

Syntaxin, a UK biotechnology company developing biopharmaceuticals to control cell secretion, has appointed Russell Greig as chairman.

Greig brings to Abingdon-based Syntaxin more than 30 years’ experience in the pharmaceutical industry. Prior to joining the company he was president of SR One, GSK’s Corporate Venture Group.

Greig spent the majority of his career at GSK, joining the company in 1980 in the discovery unit of r&d and continued to hold positions of progressive responsibility over the next three decades. He rose to president of pharmaceuticals international from 2003–2008 and senior vice president worldwide in business development for r&d.

Since 2009, Greig has been a director at Rib-X Pharmaceuticals, and a director and executive chairman at Anaphore since June 2010. He also serves as a director at Genocea Biosciences and is on the board of Edinburgh BioQuarter Commercialisation Advisory Group.

Melanie Lee, chief executive of Syntaxin, said: ‘Syntaxin is now at a transformational stage of its development. Russell's knowledge and experience will be invaluable in maximising the potential of our innovative technology platform.’

Syntaxin was founded in late 2005 through a spinout of intellectual property and scientists from the UK’s Health Protection Agency.